90 Applying Pharmacogenomics in Therapeutics5. Pharmacogenomic testing can be used to:I. Predict drug efficacy II. Predict drug toxicityIII. Guide treatment decisions, including dosinga. I onlyb. II onlyc. I and IId. II and IIIe. I, II, and IIIAnswer Key1. a2. d3. a4. b5. eREFERENCES1. FDA. Issues Advice to Make Earliest Stages of Clinical Drug Development MoreEfficient. FDA; 2006.2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev DrugDiscov 2004;3:711–5.3. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR,Schacht AL. How to improve R&D productivity: The pharmaceutical industry’s grandchallenge. Nat Rev Drug Discov 2010;9:203–14.4. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with newdrug development: Success rates for investigational drugs. Clin Pharmacol Ther2010;87:272–7.5. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceuticalR&D efficiency. Nat Rev Drug Discov 2012;11:191–200.6. McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: A decade of successes,challenges, and opportunities. Sci Transl Med 2013;5:189sr4.7. Hudis CA. Trastuzumab—Mechanism of action and use in clinical practice. N Engl JMed 2007;357:39–51.8. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D’Amico R.Trastuzumab containing regimens for early breast cancer. Cochrane Database SystRev 2012;4:CD006243.9. Pare G. Genome-wide association studies—Data generation, storage, interpretation,and bioinformatics. J Cardiovasc Transl Res 2010;3:183–8.10. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012;380:1590–605.11. Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis.Nat Rev Rheumatol 2013;9:141–53.12. Metzker ML. Sequencing technologies—The next generation. Nat Rev Genet 2010;11:31–46.13. Pavlopoulos GA, Oulas A, Iacucci E, Sifrim A, Moreau Y, Schneider R, Aerts J,Iliopoulos I. Unraveling genomic variation from next generation sequencing data.BioData Min 2013;6:13.14. Kingsmore SF, Lindquist IE, Mudge J, Gessler DD, Beavis WD. Genome-wideassociation studies: Progress and potential for drug discovery and development. NatRev Drug Discov 2008;7:221–30.
Applying Pharmacogenomics in Drug Discovery and Development9115. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI,Hageman JL, et al. A common haplotype in the complement regulatory gene factorH (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc NatlAcad Sci U S A 2005;102:7227–32.16. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, Gregori G, Penha FM,Moshfeghi AA, Zhang K, Sadda S, Feuer W, Rosenfeld PJ. Systemic complement inhibitionwith eculizumab for geographic atrophy in age-related macular degeneration:The COMPLETE study. Ophthalmology 2014;121:693–701.17. Ni Z, Hui P. Emerging pharmacologic therapies for wet age-related macular degeneration.Ophthalmologica 2009;223:401–10.18. Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, Huff CD,et al. Exome sequencing identifies the cause of a Mendelian disorder. Nat Genet2010;42:30–5.19. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinicaltrials. Nat Rev Drug Discov 2013;12:358–69.20. L’Heureux J, Murray JC, Newbury E, Shinkunas L, Simon CM. Public perspectiveson biospecimen procurement: What biorepositories should consider. BiopreservBiobank 2013;11:137–43.21. Kang B, Park J, Cho S, Lee M, Kim N, Min H, Lee S, Park O, Han B. Current status,challenges, policies, and bioethics of biobanks. Genomics Inform 2013;11:211–7.22. Tong EK, Fung LC, Stewart SL, Paterniti DA, Dang JH, Chen MS, Jr. Impact of abiospecimen collection seminar on willingness to donate biospecimens among ChineseAmericans: Results from a randomized, controlled community-based trial. CancerEpidemiol Biomarkers Prev 2014;23:392–401.23. Loffredo CA, Luta G, Wallington S, Makgoeng SB, Selsky C, Mandelblatt JS,Adams-Campbell LL. Knowledge and willingness to provide research biospecimensamong foreign-born Latinos using safety-net clinics. J Community Health 2013;38:652–9.24. Dang JH, Rodriguez EM, Luque JS, Erwin DO, Meade CD, Chen MS, Jr. Engagingdiverse populations about biospecimen donation for cancer research. J CommunityGenet 2014;5:313–27.25. Koretzky GA. The legacy of the Philadelphia chromosome. J Clin Invest 2007;117:2030–2.26. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N,Deininger MW, et al. Five-year follow-up of patients receiving imatinib for chronicmyeloid leukemia. N Engl J Med 2006;355:2408–17.27. Moore JH, Asselbergs FW, Williams SM. Bioinformatics challenges for genome-wideassociation studies. Bioinformatics 2014;26:445–55.28. Chowdhury S, Pradhan RN, Sarkar RR. Structural and logical analysis of a comprehensivehedgehog signaling pathway to identify alternative drug targets for glioma,colon and pancreatic cancer. PLoS One 2013;8:e69132.29. Schweizer L, Zhang L. Enhancing cancer drug discovery through novel cell signalingpathway panel strategy. Cancer Growth Metastasis 2013;6:53–9.30. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemiain mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824–30.31. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity andtransformation potency of bcr-abl oncogene products. Science 1990;247:1079–82.32. Honda H, Hirai H. Model mice for BCR/ABL-positive leukemias. Blood Cells MolDis 2001;27:265–78.33. Salesse S, Verfaillie CM. BCR/ABL: From molecular mechanisms of leukemia inductionto treatment of chronic myelogenous leukemia. Oncogene 2002;21:8547–59.